Darvadstrocel
| Clinical data | |
|---|---|
| Trade names | Alofisel |
| License data | |
| Routes of administration | Injection |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| KEGG | |
Darvadstrocel, sold under the brand name Alofisel, is a medication to treat complex perianal fistulas in adults with non-active/mildly active luminal Crohn's disease, when fistulas have shown an inadequate response to at least one conventional or biologic therapy.[1] It contains stem cells from the fat tissue of adult donors.[2] It is injected into the fistula tract tissue.[1]
It was approved for use in the European Union in March 2018.[2]
References
- ^ a b c "Alofisel 5 million cells/mL suspension for injection - Summary of Product Characteristics (SmPC)". (emc). 12 February 2020. Retrieved 27 February 2020.
- ^ a b "Alofisel EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 27 February 2020.
Further reading
- Kotze PG, Spinelli A, Warusavitarne J, Di Candido F, Sahnan K, Adegbola SO, Danese S (February 2019). "Darvadstrocel for the treatment of patients with perianal fistulas in Crohn's disease". Drugs Today. 55 (2): 95–105. doi:10.1358/dot.2019.55.2.2914336. PMID 30816884.
- Scott LJ (December 2018). "Darvadstrocel: A Review in Treatment-Refractory Complex Perianal Fistulas in Crohn's Disease". BioDrugs. 32 (6): 627–634. doi:10.1007/s40259-018-0311-4. PMID 30298387.
External links
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |